A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Status:
Completed
Trial end date:
2018-10-17
Target enrollment:
Participant gender:
Summary
The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement
in modified Rodnan score [mRSS]) in patients with diffuse cutaneous systemic sclerosis
(dcScc) compared to matching placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Dinesh Khanna, MD, MS
Collaborators:
Bristol-Myers Squibb National Institute of Allergy and Infectious Diseases (NIAID)